questionText: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the typical duration and severity of withdrawal symptoms associated with dopamine agonist dose reduction or discontinuation; and how those outcomes vary by starting dose, indication and duration of exposure.
answerText: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
heading: Drugs: Side Effects